The global anti-Inflammatory biologics market size was evaluated at USD 98.94 billion by 2023 and is projected to gain around USD 176.02 billion by 2033 with a CAGR of 5.93% between 2024 and 2033.
Key Takeaways
- The North America anti-inflammatory biologics market size is exhibited at USD 60.35 billion in 2023 and is expected to attain around USD 108.25 billion by 2033, poised to grow at a CAGR of 6.01% between 2024 and 2033.
- North America dominated the market with the largest revenue share of 61% in 2023.
- Europe is expected to host the fastest-growing market during the forecast period.
- By drug class, the anti-tumor necrosis factor (TNF) segment has contributed more than 45% of revenue share in 2023.
- By drug class, the interleukin antagonists segment is expected to grow at the highest CAGR in the market during the forecast period.
- By application, the rheumatoid arthritis segment dominated the market in 2023.
- By application, the psoriasis segment is expected to grow at the highest CAGR in the market during the forecast period.
- By route of administration, the injection segment dominated the market in 2023.
- By route of administration, the oral segment is expected to grow rapidly in the market in the upcoming years.
- By distributional channel, the hospital pharmacy segment dominated the market in 2023.
- By distributional channel, the retail pharmacy segment is expected to grow at the fastest rate in the market during the forecast period.
Market Overview
The Anti-Inflammatory Biologics Market focuses on biologic drugs designed to reduce inflammation, a common underlying factor in many chronic diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These biologics are typically monoclonal antibodies or fusion proteins that target specific components of the immune system to modulate inflammatory responses. The market for anti-inflammatory biologics has experienced significant growth due to advancements in biotechnology and an increasing prevalence of chronic inflammatory conditions worldwide.
Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/4507
Growth Factors
Several factors are contributing to the growth of the anti-inflammatory biologics market. Advances in biotechnology and pharmaceutical research have led to the development of more effective and targeted biologic therapies. The rising incidence of autoimmune and inflammatory diseases, driven by factors such as aging populations, environmental changes, and lifestyle choices, has increased demand for these treatments. Additionally, improved healthcare infrastructure and increased healthcare spending in developing countries are making biologic therapies more accessible to a broader patient population.
Anti-Inflammatory Biologics Market Scope
| Report Coverage | Details |
| Market Size by 2033 | USD 176.02 Billion |
| Market Size in 2023 | USD 98.94 Billion |
| Market Size in 2024 | USD 104.81 Billion |
| Market Growth Rate from 2024 to 2033 | CAGR of 5.93% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Drug Class, Application, Route of Administration, Distributional Channel, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Market Dynamics
Drivers
The primary drivers of the anti-inflammatory biologics market include the increasing prevalence of chronic inflammatory diseases and the growing awareness of biologic therapies among healthcare providers and patients. The robust pipeline of new biologic drugs in clinical development promises to expand treatment options and improve patient outcomes. Moreover, advancements in diagnostic technologies are facilitating earlier and more accurate diagnoses of inflammatory conditions, leading to timely and appropriate treatment interventions.
Opportunities
The anti-inflammatory biologics market presents numerous opportunities for growth. One significant opportunity lies in the expanding research and development efforts focused on novel biologic agents and combination therapies that could offer superior efficacy and safety profiles. Personalized medicine, driven by advances in genomics and biomarker discovery, holds the potential to tailor treatments to individual patient profiles, thereby improving therapeutic outcomes. Emerging markets, particularly in Asia-Pacific and Latin America, offer substantial growth potential due to increasing healthcare investment and a growing patient pool.
Challenges
Despite its promising growth prospects, the anti-inflammatory biologics market faces several challenges. High costs associated with biologic therapies can limit patient access and place a significant financial burden on healthcare systems. Biosimilar competition is intensifying as patents for many biologic drugs expire, potentially leading to reduced market share and pricing pressures for original biologics. Additionally, stringent regulatory requirements and complex manufacturing processes pose challenges for the timely development and approval of new biologic treatments.
Region Insights
The anti-inflammatory biologics market exhibits significant regional variation. North America dominates the market due to its well-established healthcare infrastructure, high healthcare expenditure, and a large patient population suffering from chronic inflammatory diseases. Europe follows closely, supported by favorable reimbursement policies and strong research and development activities. The Asia-Pacific region is poised for rapid growth, driven by increasing healthcare access, rising prevalence of chronic diseases, and growing investments in biotechnology. Latin America and the Middle East & Africa regions are also expected to experience growth, albeit at a slower pace, due to improving healthcare systems and rising awareness of biologic therapies.
Read Also: https://www.businesswebwire.com/data-center-networking-market/
Anti-Inflammatory Biologics Market Companies
- Amgen Inc
- Novartis AG
- AstraZeneca PLC.
- Johnson & Johnson
- PFIZER INC.
- GlaxoSmithKline plc
- F.Hoffmann-La Roche AG
- Merck & Co., Inc.
- Eli Lily and Company
Recent Developments
- In May 2024, Eisai Co., Ltd. and Biogen Inc. announced that, following the FDA’s Fast Track designation, Eisai had started rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing.
- In February 2024, the global pharmaceutical giant Hikma Pharmaceuticals PLC (Hikma) announced the U.S. launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection. COMBOGESIC® IV is an opioid-free intravenous pain reliever that combines 300 mg of nonsteroidal anti-inflammatory medication (NSAID) ibuprofen with 1,000 mg of acetaminophen.
- In June 2023, Lodoco (colchicine) was authorized by the FDA to lower the risk of cardiovascular mortality, myocardial infarction (MI), stroke, and coronary revascularization in adult patients. Lodoco, created by Agepha Pharma, is the first medication authorized to address inflammation, which is a fundamental factor in atherosclerotic cardiovascular disease.
- In January 2023, Sun Pharmaceutical Industries Limited declared that it had acquired three brands from Aksigen Hospital Care, a Mumbai-based company that treats post-operative inflammation in patients having minor surgery and dental work done. The Drugs Controller General of India (DCGI) has authorized the Disperzyme, Disperzyme-CD, and Phlogam brands.
Segment Covered in the Report
By Drug Class
- Anti-tumor Necrosis Factor (TNF)
- Interleukins Antagonists
- Janus Kinase (JAK) Inhibitor
- Others
By Application
- Rheumatoid Arthritis
- Psoriasis
- Others
By Route of Administration
- Oral
- Injection
- Intravenous
- Subcutaneous
By Distributional Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.dailystatsnews.com/